Predict your next investment

Janssen Pharmaceuticals company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
janssen.com

See what CB Insights has to offer

Investments

7

Portfolio Exits

2

Partners & Customers

10

About Janssen Pharmaceuticals

Janssen Pharmaceuticals is a pharmaceutical company that provides medicines for an array of health concerns in several therapeutic areas. These include: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer's disease, epilepsy, migraine prevention and treatment), pain management, and women's health.

Janssen Pharmaceuticals Headquarter Location

1000 U.S. Highway 202 South

Raritan, New Jersey, 08869,

United States

+1 800 775 5514

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Janssen Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Janssen Pharmaceuticals in 6 Expert Collections, including Poop Tech.

P

Poop Tech

114 items

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Microbiome

105 items

N

Nanobiotechnology

707 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

M

Medical Devices

72 items

https://www.amdm.org/members.html

Janssen Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Janssen Pharmaceuticals Rank

Research containing Janssen Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Janssen Pharmaceuticals in 4 CB Insights research briefs, most recently on Apr 6, 2021.

Latest Janssen Pharmaceuticals News

Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors

Oct 4, 2021

Geneva, Switzerland, October 4, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Dr Lütjens, Head of Discovery – Biology and Dr Rocher, Head of Discovery – Chemistry, will present today at the 10th International Meeting on Metabotropic Glutamate Receptors (October 1 – 6, 2021). Dr Paparin, Senior Manager – Chemistry, will be participating at the conference as well. In a first presentation, Dr. Rocher will discuss recent developments in our understanding of the mGlu2 receptor allosteric binding pocket and implications for drug discovery in the field of mGlu2 selective allosteric modulators. In a second presentation, Dr. Lütjens will discuss the discovery and development of ADX71149, the mGlu2 positive allosteric modulator discovered in collaboration with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, currently in a phase 2a study in epilepsy patients. In addition, Dr Lütjens and Dr Rocher will discuss the following preclinical programs, mGlu2 NAM for the treatment of mild neurocognitive disorders, mGlu3 PAM for the treatment of neurodegenerative disorders, mGlu4 PAM for the treatment of Parkinson’s disease and mGlu7 NAM for the treatment of post-traumatic stress disorder. More information on these programs can be found on our website under our pipeline section . Management will be available for one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact your conference representative or at [email protected] . About Addex Therapeutics: Addex Therapeutics  is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional “orthosteric” small molecule or biological drugs. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID), in addition to the Phase 2 clinical study for blepharospasm. Addex’s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. Contact: Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation of clinical trials. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as market conditions and regulatory review. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. Geneva, Switzerland, October 4, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Dr Robert Lütjens, Head of Discovery – Biology and Dr Jean-Philippe Rocher, Head of Discovery – Chemistry, will present at the 10th International Meeting on Metabotropic Glutamate Receptors (October 1 – 6, 2021). In their presentation, which is scheduled for Monday, October 4, 2021, Dr. Lütjens and Dr. Rocher will discuss recent developments in the following preclinical programs: mGlu2 negative allosteric modulator (NAM) for the treatment of mild neurocognitive disorders, mGlu3 positive allosteric modulator (PAM) for the treatment of neurodegenerative disorders, mGlu4 PAM for the treatment of Parkinson’s disease and mGlu7 NAM for the treatment of post-traumatic stress disorder. More information on these programs can be found on our website under our pipeline section . The Addex team will be available for one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact us at [email protected] . About Addex Therapeutics: Addex Therapeutics  is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional “orthosteric” small molecule or biological drugs. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID Addex is also investigating dipraglurant’s therapeutic use in blepharospasm, a type of dystonia, for which a clinical trial was initiated in Q3 2021. Addex’s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates with a focus in addiction. Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. Contact: Addex Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation of clinical trials. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2021, as well as market conditions and regulatory review. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. Continue Reading

Janssen Pharmaceuticals Investments

7 Investments

Janssen Pharmaceuticals has made 7 investments. Their latest investment was in Morphic Therapeutic as part of their Corporate Minority on February 2, 2019.

CBI Logo

Janssen Pharmaceuticals Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/21/2019

Corporate Minority

Morphic Therapeutic

Yes

1

1/6/2016

Project Finance

Subscribe to see more

$99M

Subscribe to see more

10

12/22/2015

Grant

Subscribe to see more

$99M

Subscribe to see more

10

9/28/2015

Project Finance

Subscribe to see more

$99M

Subscribe to see more

10

1/13/2015

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/21/2019

1/6/2016

12/22/2015

9/28/2015

1/13/2015

Round

Corporate Minority

Project Finance

Grant

Project Finance

Partnership

Company

Morphic Therapeutic

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Janssen Pharmaceuticals Portfolio Exits

2 Portfolio Exits

Janssen Pharmaceuticals has 2 portfolio exits. Their latest portfolio exit was Morphic Therapeutic on June 27, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/27/2019

IPO

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/27/2019

00/00/0000

Exit

IPO

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Sources

2

10

Janssen Pharmaceuticals Acquisitions

2 Acquisitions

Janssen Pharmaceuticals acquired 2 companies. Their latest acquisition was Hemera Biosciences - Gene Therapy Asset on December 02, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/2/2020

Acquired Unit

1

3/19/2015

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/2/2020

3/19/2015

Investment Stage

Series A

Companies

Subscribe to see more

Valuation

Total Funding

$99M

Note

Acquired Unit

Subscribe to see more

Sources

1

10

Janssen Pharmaceuticals Partners & Customers

10 Partners and customers

Janssen Pharmaceuticals has 10 strategic partners and customers. Janssen Pharmaceuticals recently partnered with HealthVerity on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/22/2021

Vendor

HealthVerity

United States

07:30 ET HealthVerity Announces Agreement with Janssen to Extend RWD and Privacy-compliant Patient Data Linkage Across their Cli...

PHILADELPHIA , Sept. 22 , 2021 / PRNewswire / -- Today HealthVerity announced an agreement with Janssen to provide access to the HealthVerity platform , the largest linked real-world data ecosystem in the US , to further facilitate critical research and development activities .

1

8/3/2021

Licensor

Zymeworks

Canada

Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms

Forward-looking statements in this press release include , but are not limited to , statements that relate to Zymeworks Inc. ' expectations regarding the receipt of payments under its licensing agreement with Janssen , the continued importance of Zymeworks Inc. ' platform technologies to its business model , and other information that is not historical information .

2

5/31/2021

Partner

Qu & Co

Netherlands

Qu&Co announces multi-year research collaboration with Janssen Pharmaceuticals to develop and test quantum computational methods for applications in pharma R&D

Amsterdam , 31 May 2021 - Qu & Co announces multi-year research collaboration with Janssen Pharmaceuticals , Inc. to develop and test quantum computational methods for applications in pharma R&D .

1

5/18/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/20/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/22/2021

8/3/2021

5/31/2021

5/18/2021

4/20/2021

Type

Vendor

Licensor

Partner

Licensor

Licensor

Business Partner

HealthVerity

Zymeworks

Qu & Co

Country

United States

Canada

Netherlands

Subscribe to see more

Subscribe to see more

News Snippet

07:30 ET HealthVerity Announces Agreement with Janssen to Extend RWD and Privacy-compliant Patient Data Linkage Across their Cli...

PHILADELPHIA , Sept. 22 , 2021 / PRNewswire / -- Today HealthVerity announced an agreement with Janssen to provide access to the HealthVerity platform , the largest linked real-world data ecosystem in the US , to further facilitate critical research and development activities .

Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms

Forward-looking statements in this press release include , but are not limited to , statements that relate to Zymeworks Inc. ' expectations regarding the receipt of payments under its licensing agreement with Janssen , the continued importance of Zymeworks Inc. ' platform technologies to its business model , and other information that is not historical information .

Qu&Co announces multi-year research collaboration with Janssen Pharmaceuticals to develop and test quantum computational methods for applications in pharma R&D

Amsterdam , 31 May 2021 - Qu & Co announces multi-year research collaboration with Janssen Pharmaceuticals , Inc. to develop and test quantum computational methods for applications in pharma R&D .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Janssen Pharmaceuticals Team

29 Team Members

Janssen Pharmaceuticals has 29 team members, including current Chief Executive Officer, Matthew Mulvey.

Name

Work History

Title

Status

Matthew Mulvey

Chief Executive Officer

Current

Tom Cavanaugh

Janssen, Celgene, and Pharmacia Corporation

President

Current

David Jimenez Lopez

President

Current

Candice Long

Johnson & Johnson, and Janssen Pharmaceutica

President

Current

Stef HEYLEN

Chief Operating Officer

Current

Name

Matthew Mulvey

Tom Cavanaugh

David Jimenez Lopez

Candice Long

Stef HEYLEN

Work History

Janssen, Celgene, and Pharmacia Corporation

Johnson & Johnson, and Janssen Pharmaceutica

Title

Chief Executive Officer

President

President

President

Chief Operating Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.